<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pseudoephedrine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pseudoephedrine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pseudoephedrine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9833" href="/d/html/9833.html" rel="external">see "Pseudoephedrine: Drug information"</a> and <a class="drug drug_patient" data-topicid="11892" href="/d/html/11892.html" rel="external">see "Pseudoephedrine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F215332"><span class="drugH1">Brand Names: US</span>
<ul>
<li>FT Nasal Decongestant Max Str [OTC];</li>
<li>Nasal Decongestant [OTC];</li>
<li>Nexafed [OTC] [DSC];</li>
<li>Shopko Nasal Decongestant Max [OTC] [DSC];</li>
<li>Shopko Nasal Decongestant [OTC] [DSC];</li>
<li>Simply Stuffy [OTC];</li>
<li>Sudafed Childrens [OTC];</li>
<li>Sudafed Congestion [OTC] [DSC];</li>
<li>Sudafed Sinus Congestion 12HR [OTC];</li>
<li>Sudafed Sinus Congestion 24HR [OTC];</li>
<li>Sudafed Sinus Congestion [OTC];</li>
<li>Sudafed [OTC];</li>
<li>SudoGest 12 Hour [OTC];</li>
<li>SudoGest Maximum Strength [OTC];</li>
<li>SudoGest [OTC];</li>
<li>Suphedrine 12Hour [OTC];</li>
<li>Zephrex-D [OTC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1061613"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Adrenergic Agonist Agent</span>;</li>
<li>
<span class="list-set-name">Decongestant</span>;</li>
<li>
<span class="list-set-name">Sympathomimetic</span></li></ul></div>
<div class="block dop drugH1Div" id="F215352"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Safety and efficacy for the use of cough and cold products in infants and young children is limited; the AAP warns against the use of these products for respiratory illnesses in infants and young children; the FDA does not recommend OTC use in infants and children &lt;2 years of age due to the risk of serious and life-threatening adverse effects (including death) and recommends to use with caution in pediatric patients ≥2 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1','lexi-content-ref-FDA.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1','lexi-content-ref-FDA.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aa6069be-77fb-4807-b092-cbf82db43773">Nasal congestion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nasal congestion (decongestant):</b> Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;4 years: Limited data available: Immediate release: 1 mg/kg/dose every 6 hours; maximum dose: 15 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gentile.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gentile.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 4 to &lt;6 years: Immediate release:</p>
<p style="text-indent:-2em;margin-left:6em;">Fixed dose: 15 mg every 4 to 6 hours; maximum daily dose: 60 mg/<b>24 hours</b></p>
<p style="text-indent:-2em;margin-left:6em;">Weight-directed dosing: 1 mg/kg/dose every 6 hours; maximum dose: 15 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gentile.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gentile.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to &lt;12 years: Immediate release: 30 mg every 4 to 6 hours; maximum daily dose: 120 mg/<b>24 hours </b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate release: 60 mg every 4 to 6 hours; maximum daily dose: 240 mg/day</p>
<p style="text-indent:-2em;margin-left:6em;">Extended release: 120 mg every 12 hours <b>or</b> 240 mg once daily; maximum daily dose: 240 mg/<b>24 hours </b></p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51159523"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51159524"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F215337"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9833" href="/d/html/9833.html" rel="external">see "Pseudoephedrine: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0cba8594-a9d4-4784-9f98-632ce0f71f3a">Hyperlactation, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperlactation, treatment (off-label use): Oral: </b>Immediate release: 30 mg as a single dose. If milk production is not decreased after 8 to 12 hours, may administer a single dose of 60 mg. Most patients require single, as-needed doses; others may require scheduled dosing. Dosage range: 30 to 60 mg once to twice daily as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32031417']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32031417'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aa6069be-77fb-4807-b092-cbf82db43773">Nasal congestion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nasal congestion:</b> General dosing guidelines: <b>Oral:</b> Immediate release: 60 mg every 4 to 6 hours; Extended release: 120 mg every 12 hours <b>or</b> 240 mg every 24 hours; maximum: 240 mg per 24 hours.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991701"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, pseudoephedrine is substantially eliminated in the urine and patients with kidney impairment are at increased risk of accumulation. Consider using reduced doses (especially if therapy is longer-term) and monitor for adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7507589']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7507589'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989022"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F215306"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Cardiac arrhythmia, chest tightness, circulatory shock (with hypotension), hypertension, palpitations, tachycardia</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Ataxia, central nervous system stimulation (transient), chills, confusion, dizziness, drowsiness, excitability, fatigue, hallucination, headache, insomnia, nervousness, neuritis, restlessness, seizure, vertigo</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Diaphoresis, skin photosensitivity, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Anorexia, constipation, diarrhea, dry throat, ischemic colitis, nausea, vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:2em;">Genitourinary: Difficulty in micturition, dysuria, urinary retention</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Agranulocytosis, hemolytic anemia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Anaphylaxis</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Tremor, weakness</p>
<p style="text-indent:-2em;margin-left:2em;">Ophthalmic: Blurred vision, diplopia</p>
<p style="text-indent:-2em;margin-left:2em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:2em;">Renal: Polyuria</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Dry nose, dyspnea, nasal congestion, pharyngeal edema, thickening of bronchial secretions, wheezing</p></div>
<div class="block coi drugH1Div" id="F215318"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">OTC labeling: When used for self-medication, do not use with or within 2 weeks of discontinuing a monoamine oxidase inhibitor.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F215303"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sodium: Some products may contain sodium.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Self-medication (OTC use): When used for self-medication (OTC), notify health care provider to use if you have diabetes, heart disease, high BP, thyroid disease, difficultly in urination due to enlargement of the prostate gland, or obstruction/narrowing of the bowel (ER products). Discontinue use and notify health care provider if symptoms do not improve within 7 days or are accompanied by fever or if nervousness, dizziness, or sleeplessness occur.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878613"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Safety and efficacy for the use of cough and cold products in pediatric patients &lt;4 years of age is limited; the AAP warns against the use of these products for respiratory illnesses in young children. Serious adverse effects including death have been reported (in some cases, high blood concentrations of pseudoephedrine were found). Many of these products contain multiple active ingredients, increasing the risk of accidental overdose when used with other products. The FDA does not recommend OTC uses for these products in pediatric patients &lt;2 years of age and recommends to use with caution in pediatric patients ≥2 years of age. Health care providers are reminded to ask caregivers about the use of OTC cough and cold products in order to avoid exposure to multiple medications containing the same ingredient (AAP 2018; CDC 2007; FDA 2017; FDA 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F215313"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Liquid, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sudafed Childrens: 15 mg/5 mL (118 mL) [alcohol free, sugar free; contains edetate (edta) disodium, fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye), menthol, polyethylene glycol (macrogol), saccharin sodium, sodium benzoate; grape flavor]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Nasal Decongestant Max Str: 30 mg [contains fd&amp;c red #40(allura red ac)aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nasal Decongestant: 30 mg [contains fd&amp;c red #40(allura red ac)aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nasal Decongestant: 30 mg [contains fd&amp;c red #40(allura red ac)aluminum lake, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Shopko Nasal Decongestant Max: 30 mg [DSC] [contains fd&amp;c red #40(allura red ac)aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Simply Stuffy: 30 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sudafed: 30 mg [contains fd&amp;c red #40(allura red ac)aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sudafed Congestion: 30 mg [DSC] [contains fd&amp;c red #40(allura red ac)aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sudafed Sinus Congestion: 30 mg [contains fd&amp;c red #40(allura red ac)aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">SudoGest: 30 mg [contains fd&amp;c red #40(allura red ac)aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">SudoGest: 60 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">SudoGest: 60 mg [DSC] [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">SudoGest Maximum Strength: 30 mg [gluten free; contains fd&amp;c red #40(allura red ac)aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 30 mg, 60 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Abuse-Deterrent, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nexafed: 30 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zephrex-D: 30 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 12 Hour, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">FT Nasal Decongestant Max Str: 120 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Shopko Nasal Decongestant: 120 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sudafed Sinus Congestion 12HR: 120 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">SudoGest 12 Hour: 120 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Suphedrine 12Hour: 120 mg [gluten free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 120 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sudafed Sinus Congestion 24HR: 240 mg</p></div>
<div class="block geq drugH1Div" id="F215299"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F3422279"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Liquid</b> (Sudafed Childrens Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg/5 mL (per mL): $0.05</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet Abuse-Deterrent</b> (Zephrex-D Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $0.23</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 12-hour</b> (Pseudoephedrine HCl ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $0.25 - $0.38</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 12-hour</b> (Sudafed Sinus Congestion 12HR Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $0.46</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Sudafed Sinus Congestion 24HR Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">240 mg (per each): $1.11</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Pseudoephedrine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $0.10</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $0.07</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Sudafed Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $0.19</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Sudafed Sinus Congestion Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $0.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (SudoGest Maximum Strength Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $0.05</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (SudoGest Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $0.03</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $0.09</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adip drugH1Div" id="F53568400"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;">Because ephedrine and pseudoephedrine have been used to synthesize methamphetamine, the DEA has placed them in the category of “Schedule Listed Products”; restrictions are in place to reduce the potential for misuse (diversion) and abuse (eg, storage requirements, additional documentation of sale); the DEA limit for a single transaction to a single individual for drug products containing ephedrine or pseudoephedrine is 3.6 g/24 hours, 9 g/30 days, or if mail-order transaction 7.5 g/30 days. </p></div>
<div class="block admp drugH1Div" id="F52613734"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with water or milk to decrease GI distress; swallow timed release tablets or capsules whole, do not chew or crush; Sudafed 24 Hour tablet may not completely dissolve and appear in stool</p></div>
<div class="block adm drugH1Div" id="F803184"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral: </b>Do not crush ER drug product, swallow whole. May administer with or without food. Sudafed 24 Hour tablet may not completely dissolve and appear in stool.</p>
<p style="text-indent:-2em;margin-left:2em;">Bariatric surgery: Tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. ER tablets should be swallowed whole. Do not crush or chew. IR tablet, chewable tablet, capsule, oral solution, syrup, and suspension formulations are available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery.</p></div>
<div class="block sts drugH1Div" id="F57490532"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at room temperature.</p></div>
<div class="block usep drugH1Div" id="F53568580"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Temporary symptomatic relief of nasal congestion due to common cold, upper respiratory allergies, and sinusitis; also promotes nasal or sinus drainage (immediate release formulations: FDA approved in ages &gt;4 years and adults; extended release formulations: FDA approved in ages &gt;12 years and adults). <b>Note:</b> Approved ages and uses for generic products may vary; consult labeling for specific information. </p></div>
<div class="block mst drugH1Div" id="F215371"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Sudafed may be confused with sotalol, Sudafed PE, Sufenta</p>
<p style="text-indent:-2em;margin-left:4em;">Sudafed 12 Hour may be confused with Sudafed 12 Hour Pressure + Pain</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299959"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F215308"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alkalinizing Agents: May increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Management: Consider alternatives to this combination when possible. If combined, monitor for hypertension and tachycardia, and do not coadminister these agents for more than 10 days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbonic Anhydrase Inhibitors: May increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroprocaine (Systemic): May enhance the hypertensive effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): May enhance the vasoconstricting effect of Alpha-/Beta-Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: Decongestants may decrease the serum concentration of FentaNYL. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iobenguane Radiopharmaceutical Products: Alpha-/Beta-Agonists (Indirect-Acting) may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products.  Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the adverse/toxic effect of Sympathomimetics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Consider initial dose reductions of sympathomimetic agents, and closely monitor for enhanced blood pressure elevations, in patients receiving linezolid.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the hypertensive effect of Alpha-/Beta-Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting). While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to linezolid specific monographs for details.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pergolide: May enhance the hypertensive effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reserpine: May diminish the therapeutic effect of Alpha-/Beta-Agonists (Indirect-Acting).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists. Management: If possible, avoid coadministration of direct-acting alpha-/beta-agonists and serotonin/norepinephrine reuptake inhibitors. If coadministered, monitor for increased sympathomimetic effects (eg, increased blood pressure, chest pain, headache).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha-/Beta-Agonists. Management: Avoid, if possible, the use of alpha-/beta-agonists in patients receiving tricyclic antidepressants. If combined, monitor for evidence of increased pressor effects and consider reductions in initial dosages of the alpha-/beta-agonist.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urinary Acidifying Agents: May decrease the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting).<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F215328"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;text-align:justify;display:inline">Onset of effect may be delayed if pseudoephedrine is taken with food. Management: Administer without regard to food.</p></div>
<div class="block dic drugH1Div" id="F215320"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain sodium.</p></div>
<div class="block rep_considerations drugH1Div" id="F56522528"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Pseudoephedrine has been studied for the treatment of retrograde ejaculation. Additional studies are needed to determine effectiveness and appropriate dosing. Information related to pregnancy and live birth rates following treatment is lacking (Arafa 2008; ESSM [Capogrosso 2021]; Shoshany 2017).</p></div>
<div class="block pri drugH1Div" id="F5630944"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Use of pseudoephedrine during the first trimester may be associated with an increased risk of congenital anomalies, possibly due to vasoconstrictive effects; however, additional studies are needed (Elliott 2009; Werler 2002; Werler 2003; Werler 2006; Yau 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Blood flow to the uterine artery, fetal aorta, and umbilical artery were not affected by a single maternal dose of immediate-acting pseudoephedrine 60 mg administered to 12 women in their third trimester of pregnancy (26 to 40 weeks' gestation). Mother and fetus were monitored for 3 hours after the dose. There was no change in maternal BP and no change in maternal or fetal heart rate (Smith 1990). Fetal tachycardia was reported following use of ER pseudoephedrine 120 mg once daily for 7 days by a mother prior to a nonstress test at 39 weeks' gestation. The same tests completed prior to pseudoephedrine exposure were normal (Anastasio 1992).</p>
<p style="text-indent:0em;margin-top:2em;">Decongestants are not the preferred agents for the treatment of rhinitis during pregnancy due to their low or variable maternal benefit and potential fetal harm. Oral pseudoephedrine should be avoided during the first trimester. Prolonged use later in pregnancy should also be avoided (AAAAI/ACAAI [Dykewicz 2020]).</p></div>
<div class="block pha drugH1Div" id="F215302"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Directly stimulates alpha-adrenergic receptors of respiratory mucosa causing vasoconstriction; directly stimulates beta-adrenergic receptors causing bronchial relaxation, increased heart rate and contractility</p></div>
<div class="block phk drugH1Div" id="F215317"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Decongestant: Oral: 30 minutes (Chua, 1989)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Peak effect: Decongestant: Oral: ~1-2 hours (Chua, 1989)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: Immediate release tablet: 3-8 hours (Chua, 1989) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Rapid (Simons, 1996)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: Children: ~2.5 L/kg (Simons, 1996); Adults: 2.64-3.51 L/kg (Kanfer, 1993)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Undergoes n-demethylation to norpseudoephedrine (active) (Chua, 1989; Kanfer, 1993); Hepatic (&lt;1%) (Kanfer, 1993)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Varies by urine pH and flow rate; alkaline urine decreases renal elimination of pseudoephedrine (Kanfer, 1993)</p>
<p style="text-indent:-2em;margin-left:4em;">Children: ~3 hours (urine pH ~6.5) (Simons, 1996)</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 9-16 hours (pH 8); 3-6 hours (pH 5) (Chua, 1989)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak:</p>
<p style="text-indent:-2em;margin-left:4em;">Children (immediate release) ~2 hours (Simons, 1996)</p>
<p style="text-indent:-2em;margin-left:4em;">Adults (immediate release): 1-3 hours (dose dependent) (Kanfer, 1993)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (43% to 96% as unchanged drug, 1% to 6% as active norpseudoephedrine); dependent on urine pH and flow rate; alkaline urine decreases renal elimination of pseudoephedrine (Kanfer, 1993)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F215321"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Sedofan II | Sudafed</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Mex 24</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apohealth sinus nasal decongestant | Blooms the chemist sinus nasal decongestant | Chemists' own sinus relief | Chemmart sinus nasal decongestant | Decongestant | Hs | Logicin sinus | Nasal Decongestant | Nyal + decongest | O/n sinus + | Pharmacy action sinus &amp; nasal decongestant re | Pharmacy care sinus &amp; nasal relief | Pharmacy choice sinus nasal decongestant | Pseudoephedrin | Sinus relief | Sudafed | Trust sinus and nasal decongestant</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Sudafed | Sudorin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Otrivine nasa | Rinomar Pseudo-Ephedrinum | Vasocedine Pseudoephedrine</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Dexan | Respirex</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">De li tong | Lei meng te | Ni ke | Pseudoephedrine co | Tai kang xin</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Sudafed</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Sudafed</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Pseudoephedrine | Sudafed decongestant elixir | Sudophine</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Sudafed</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Galpseud | Galsud | Sudafed | Sudafed 12 hour</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Arti drine | Cosac | Decofed | Logicin sinus | Neo-Fed | Noscol | Pseudoephedrine | Sinu-e | Subilin | Sudodrine | Syncodrin | Uni-Sufed | Vicodrine | Vidadrine | Zudo</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Disudrin | Sudafed</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Sudafed</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Sinufed | Tarophed</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Dolcy | Sudafed</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Psophedrin | Sofedrin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Kopseu | Pharma pseudoephedrine hcl | Pseudafed | Pseudapen | Pseupherin | Sudafed</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Sudafed</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Sudafed</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Sudafed</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Drill expectorant | Vasocedine Pseudoephedrine</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Sudafed</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Dofedrin | Sudafed</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Pseudorine | Sedo | Sudafed</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apohealth sinus nasal decongestant | Sudafed | Sudomyl</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Tridecon</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Apselan | Sudafed</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Afrin | Decongestant | Elixsure Congestion | Nexafed | Pseudoephedrin Hydrochloride | Pseudoephedrine HCL | Q-Fed | Silfedrine | Sinus decongestant | Sudafed | Sudafed 12 hour | Sudafed child | Sudanyl | Sudodrin | Sudogest | Suphedrine | Tylenol simply stuffy</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Pseudoefedrina | Sudafed</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Galpseud</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Sudafed</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Pseudorine | Sudafed</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Maxiphed | Pseudoephedrine | Pseudophrine | Rhinofed | Rhinophed | Sudo Med</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Sudafed</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Dekoferin | Eksofed | Rinogest | Sudafed</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Fedcen | Novazil | Pseubyirin | Pseudoephedrine | Psubity | Seudorin | Smooth | Subilin | Suffin | Sufolin | Supian | Zhiti</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Acunaso | Adco-sufedrin | Demazin decongestant | Drilix | Drinasal s | Drixine | Drixora | Flutex decon-s | Monofed | Sinu med ped | Sinumed | Symptofed</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Drilix | Sudafed</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pseudoephedrine-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12848771">
<a name="12848771"></a>Aljazaf K, Hale TW, Ilett KF, et al. Pseudoephedrine: effects on milk production in women and estimation of infant exposure via breastmilk. <i>Br J Clin Pharmacol</i>. 2003;56(1):18-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pseudoephedrine-pediatric-drug-information/abstract-text/12848771/pubmed" id="12848771" target="_blank">12848771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). Cough and cold medicines should not be prescribed, recommended or used for respiratory illnesses in young children. Updated June 12, 2018. http://www.choosingwisely.org/clinician-lists/american-academy-pediatrics-cough-and-cold-medicines-for-children-under-four/
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pseudoephedrine-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1414455">
<a name="1414455"></a>Anastasio GD, Harston PR. Fetal tachycardia associated with maternal use of pseudoephedrine, an over-the-counter oral decongestant. <i>J Am Board Fam Pract</i>. 1992;5(5):527-528.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pseudoephedrine-pediatric-drug-information/abstract-text/1414455/pubmed" id="1414455" target="_blank">1414455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pseudoephedrine-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17433085">
<a name="17433085"></a>Arafa M, El Tabie O. Medical treatment of retrograde ejaculation in diabetic patients: a hope for spontaneous pregnancy. <i>J Sex Med</i>. 2008;5(1):194-198. doi:10.1111/j.1743-6109.2007.00456.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pseudoephedrine-pediatric-drug-information/abstract-text/17433085/pubmed" id="17433085" target="_blank">17433085</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34090242">
<a name="34090242"></a>Capogrosso P, Jensen CFS, Rastrelli G, et al. Male sexual dysfunctions in the infertile couple-recommendations from the European Society of Sexual Medicine (ESSM). <i>Sex Med</i>. 2021;9(3):100377. doi:10.1016/j.esxm.2021.100377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pseudoephedrine-pediatric-drug-information/abstract-text/34090242/pubmed" id="34090242" target="_blank">34090242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pseudoephedrine-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17218934">
<a name="17218934"></a>Centers for Disease Control and Prevention (CDC). Infant deaths associated with cough and cold medications--two states, 2005. <i>MMWR Morb Mortal Wkly Rep</i>. 2007;56(1):1-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pseudoephedrine-pediatric-drug-information/abstract-text/17218934/pubmed" id="17218934" target="_blank">17218934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2647163">
<a name="2647163"></a>Chua SS, Benrimoj SI, Triggs EJ. Pharmacokinetics of Non-Prescription Sympathomimetic Agents. <i>Biopharm Drug Dispos</i>. 1989;10(1):1-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pseudoephedrine-pediatric-drug-information/abstract-text/2647163/pubmed" id="2647163" target="_blank">2647163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32707227">
<a name="32707227"></a>Dykewicz MS, Wallace DV, Amrol DJ, et al; Workgroup Contributors. Rhinitis 2020: a practice parameter update.<i> J Allergy Clin Immunol</i>. 2020;146(4):721-767. doi:10.1016/j.jaci.2020.07.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pseudoephedrine-pediatric-drug-information/abstract-text/32707227/pubmed" id="32707227" target="_blank">32707227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19884590">
<a name="19884590"></a>Elliott L, Loomis D, Lottritz L, Slotnick RN, Oki E, Todd R. Case-control study of a gastroschisis cluster in Nevada. <i>Arch Pediatr Adolesc Med</i>. 2009;163(11):1000-1006. doi:10.1001/archpediatrics.2009.186<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pseudoephedrine-pediatric-drug-information/abstract-text/19884590/pubmed" id="19884590" target="_blank">19884590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6529531">
<a name="6529531"></a>Findlay JW, Butz RF, Sailstad JM, et al. Pseudoephedrine and Triprolidine in Plasma and Breast Milk of Nursing Mothers. <i>Br J Clin Pharmacol</i>. 1984;18(6):901-906.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pseudoephedrine-pediatric-drug-information/abstract-text/6529531/pubmed" id="6529531" target="_blank">6529531</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>Food and Drug Administration (FDA). Most young children with a cough or cold don't need medicines. July 18, 2017. <a href="https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm422465.htm" target="_blank">https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm422465.htm</a>. Accessed November 2, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2">
<a name="FDA.2"></a>Food and Drug Administration (FDA). Use caution when giving cough and cold products to kids. Updated February 8, 2018. <a href="https://www.fda.gov/drugs/resourcesforyou/specialfeatures/ucm263948.htm" target="_blank">https://www.fda.gov/drugs/resourcesforyou/specialfeatures/ucm263948.htm</a>. Accessed November 2, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gentile.1">
<a name="Gentile.1"></a>Gentile DA, Friday GA, Skoner DP. Management of Allergic Rhinitis: Antihistamines and Decongestants. <i>Immunol Allergy Clin NA</i>. 2000;20(2):355-368.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8498418">
<a name="8498418"></a>Ito S, Blajchman A, Stephenson M, et al. Prospective Follow-Up of Adverse Reactions in Breast-Fed Infants Exposed to Maternal Medication. <i>Am J Obstet Gynecol</i>. 1993;168(5):1393-1399.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pseudoephedrine-pediatric-drug-information/abstract-text/8498418/pubmed" id="8498418" target="_blank">8498418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pseudoephedrine-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32031417">
<a name="32031417"></a>Johnson HM, Eglash A, Mitchell KB, et al; Academy of Breastfeeding Medicine. ABM clinical protocol #32: management of hyperlactation. <i>Breastfeed Med</i>. 2020;15(3):129-134. doi:10.1089/bfm.2019.29141.hmj<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pseudoephedrine-pediatric-drug-information/abstract-text/32031417/pubmed" id="32031417" target="_blank">32031417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7507589">
<a name="7507589"></a>Kanfer I, Dowse R, Vuma V. Pharmacokinetics of Oral Decongestants. <i>Pharmacotherapy</i>. 1993;13(6, pt 2):116-128; discussion 143-146.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pseudoephedrine-pediatric-drug-information/abstract-text/7507589/pubmed" id="7507589" target="_blank">7507589</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Nexafed (pseudoephedrine) [prescribing information]. Palatine, IL: Acura Pharmaceuticals; October 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pseudoephedrine-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28380686">
<a name="28380686"></a>Shoshany O, Abhyankar N, Elyaguov J, Niederberger C. Efficacy of treatment with pseudoephedrine in men with retrograde ejaculation. <i>Andrology</i>. 2017;5(4):744-748. doi:10.1111/andr.12361<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pseudoephedrine-pediatric-drug-information/abstract-text/28380686/pubmed" id="28380686" target="_blank">28380686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8917241">
<a name="8917241"></a>Simons FE, Gu X, Watson WT, et al. Pharmacokinetics of the Orally Administered Decongestants Pseudoephedrine and Phenylpropanolamine in Children. <i>J Pediatr</i>. 1996;129(5):729-734.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pseudoephedrine-pediatric-drug-information/abstract-text/8917241/pubmed" id="8917241" target="_blank">8917241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2216228">
<a name="2216228"></a>Smith CV, Rayburn WF, Anderson JC, Duckworth AF, Appel LL. Effect of a single dose of oral pseudoephedrine on uterine and fetal Doppler blood flow. <i>Obstet Gynecol</i>. 1990;76(5, pt 1):803-806. doi:10.1097/00006250-199011000-00015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pseudoephedrine-pediatric-drug-information/abstract-text/2216228/pubmed" id="2216228" target="_blank">2216228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25183382">
<a name="25183382"></a>Soussan C, Gouraud A, Portolan G, et al. Drug-induced adverse reactions via breastfeeding: a descriptive study in the French Pharmacovigilance Database. <i>Eur J Clin Pharmacol</i>. 2014;70(11):1361-1366.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pseudoephedrine-pediatric-drug-information/abstract-text/25183382/pubmed" id="25183382" target="_blank">25183382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sudafed.2019.02">
<a name="Sudafed.2019.02"></a>Sudafed (pseudoephedrine) [prescribing information]. Fort Washington, PA: McNeil Consumer Healthcare Division; received February 2019.</div>
</li>
<li>
<div class="reference">
                  Sudafed 24 hour (pseudoephedrine) [prescribing information]. Fort Washington, PA: McNeil Consumer Healthcare; received August 2019.</div>
</li>
<li>
<div class="reference">
                  Sudafed liquid (pseudoephedrine) [prescribing information]. Fort Washington, PA: McNeil Laboratories.</div>
</li>
<li>
<div class="reference">
                  Sudafed tablets (pseudoephedrine) [prescribing information]. Fort Washington, PA: McNeil Laboratories.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16933214">
<a name="16933214"></a>Werler MM. Teratogen Update: Pseudoephedrine. <i>Birth Defects Res A Clin Mol Teratol</i>. 2006;76(6):445-452.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pseudoephedrine-pediatric-drug-information/abstract-text/16933214/pubmed" id="16933214" target="_blank">16933214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12859037">
<a name="12859037"></a>Werler MM, Sheehan JE, Mitchell AA. Association of vasoconstrictive exposures with risks of gastroschisis and small intestinal atresia. <i>Epidemiology</i>. 2003;14(3):349-354.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pseudoephedrine-pediatric-drug-information/abstract-text/12859037/pubmed" id="12859037" target="_blank">12859037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11772781">
<a name="11772781"></a>Werler MM, Sheehan JE, Mitchell AA. Maternal medication use and risks of gastroschisis and small intestinal atresia. <i>Am J Epidemiol</i>. 2002;155(1):26-31. doi:10.1093/aje/155.1.26<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pseudoephedrine-pediatric-drug-information/abstract-text/11772781/pubmed" id="11772781" target="_blank">11772781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23825167">
<a name="23825167"></a>Yau WP, Mitchell AA, Lin KJ, Werler MM, Hernández-Díaz S. Use of decongestants during pregnancy and the risk of birth defects. <i>Am J Epidemiol</i>. 2013;178(2):198-208. doi:10.1093/aje/kws427<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pseudoephedrine-pediatric-drug-information/abstract-text/23825167/pubmed" id="23825167" target="_blank">23825167</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Zephrex-D (pseudoephedrine) [prescribing information]. Allegan, MI: Perrigo; received January 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 12747 Version 486.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
